Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
Status:
Completed
Trial end date:
2017-01-30
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label study to assess the safety, pharmacokinetics,
pharmacodynamics, and preliminary efficacy of talazoparib in patients with advanced tumors
with DNA-repair pathway deficiencies. There will be 2 parts to the study: a dose escalation
phase in which the maximum tolerated dose will be defined, and a dose expansion phase.